Related Experiment Video

Updated: May 22, 2026

Development of Inhibitors of Protein-protein Interactions through REPLACE: Application to the Design and Development Non-ATP Competitive CDK Inhibitors
10:33

Development of Inhibitors of Protein-protein Interactions through REPLACE: Application to the Design and Development Non-ATP Competitive CDK Inhibitors

Published on: October 26, 2015

Perspective of cyclin-dependent kinase 9 (CDK9) as a drug target

Vladimír Krystof1, Sonja Baumli, Robert Fürst

  • 1Laboratory of Growth Regulators, Palacký University, Šlechtitelů 11, 78371, Olomouc, Czech Republic. vladimir.krystof@upol.cz

Current Pharmaceutical Design
|May 11, 2012
PubMed

Insights

Cyclin-dependent kinases (CDKs) are implicated in cancer. This review focuses on CDK9 as a specific target for anticancer drugs, exploring structural biology insights for developing targeted therapies and discussing its role in inflammation.

Area of Science:

  • Biochemistry
  • Molecular Biology
  • Pharmacology

Background:

  • Deregulation of cyclin-dependent kinases (CDKs) is linked to various cancers, driving interest in therapeutic inhibitors.
  • Most existing CDK inhibitors lack specificity, targeting multiple CDKs.
  • Recent research identifies CDK9 as a key mediator of anticancer effects for evaluated drugs.

Purpose of the Study:

  • To review recent structural biology findings relevant to developing specific CDK9 inhibitors.
  • To explore the potential of highly specific CDK9 inhibitors in cancer therapy.
  • To highlight the involvement of CDK9 in inflammatory conditions.

Main Methods:

  • Literature review of structural biology studies on CDK9.
  • Analysis of existing CDK inhibitor selectivity.
  • Discussion of CDK9's role in cancer and inflammation.

Main Results:

  • Structural insights may enable the development of highly selective CDK9 inhibitors.
  • CDK9 is identified as a critical target for anticancer drug activity.
  • CDK9 plays a role in inflammatory processes and diseases.

Conclusions:

  • Targeting CDK9 specifically offers a promising strategy for cancer therapy.
  • Further research into CDK9's structure and function can advance drug development.
  • CDK9 inhibition may have implications beyond cancer treatment, including inflammatory diseases.

More Related Videos

Identification of Cyclin-dependent Kinase 1 Specific Phosphorylation Sites by an In Vitro Kinase Assay12:26

Identification of Cyclin-dependent Kinase 1 Specific Phosphorylation Sites by an In Vitro Kinase Assay

Published on: May 3, 2018

Identification of Novel CK2 Kinase Substrates Using a Versatile Biochemical Approach11:11

Identification of Novel CK2 Kinase Substrates Using a Versatile Biochemical Approach

Published on: February 21, 2019

Related Concept Videos

M-Cdk Drives Transition Into Mitosis02:15

M-Cdk Drives Transition Into Mitosis

Checkpoints throughout the cell cycle serve as safeguards and gatekeepers, allowing the cell cycle to progress in favorable conditions and slow or halt it in problematic ones. This regulation is known as the cell cycle control system.
Cyclin-dependent kinases, or Cdks, work in concert with cyclins to control cell cycle transitions. M-Cdk, a complex of Cdk1 bound to M cyclin, is a well-known example of this coordinated control that drives the transition from the G2 to the M phase.
M cyclin...
M-Cdk Drives Transition Into Mitosis02:15

M-Cdk Drives Transition Into Mitosis

Checkpoints throughout the cell cycle serve as safeguards and gatekeepers, allowing the cell cycle to progress in favorable conditions and slow or halt it in problematic ones. This regulation is known as the cell cycle control system.
Cyclin-dependent kinases, or Cdks, work in concert with cyclins to control cell cycle transitions. M-Cdk, a complex of Cdk1 bound to M cyclin, is a well-known example of this coordinated control that drives the transition from the G2 to the M phase.
M cyclin...
Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
Inhibition of CDK Activity02:34

Inhibition of CDK Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
Positive Regulator Molecules02:39

Positive Regulator Molecules

Mitotic cell division results in daughter cells that exactly resemble the parent cell. However, errors in the DNA replication or distribution of genetic material may lead to genetic mutations that may be passed down to every new cell formed from the resulting abnormal cell. Propagation of such mutant cells is restricted through checkpoint mechanisms present at different stages of the cell cycle. These checkpoints involve regulator molecules that either promote or demote cell cycle events.
Positive Regulator Molecules01:45

Positive Regulator Molecules

To consistently produce healthy cells, the cell cycle—the process that generates daughter cells—must be precisely regulated.